文献速递呼吸道感染肺栓塞与肺血管病

COVID-19肺炎住院患者血栓的预防与管理

Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia.
PubMed 文献 · Lancet Respir Med · 2021-11-25

本文为观点性综述,总结SARS-CoV-2感染相关血栓形成病理生理、实验室与临床特征,并讨论住院重症COVID-19患者凝血病管理要点,包括凝血评估、血栓并发症识别、抗血栓预防与治疗性抗凝,并等待出院后延长血栓预防试验结果。

要点

  • SARS-CoV-2感染炎症反应可致急性期反应和内皮功能障碍,参与COVID-19相关凝血病。
  • COVID-19相关凝血病临床与实验室特征部分不同于经典弥散性血管内凝血。
  • 住院重症COVID-19需评估凝血、识别血栓并发症并考虑抗血栓预防或治疗性抗凝。

核心结论

  • 部分SARS-CoV-2感染者发展为中型或重型COVID-19,血栓栓塞并发症风险增加。
  • 需理解COVID-19血栓病理生理以制定管理与预防策略,影响短期和长期健康结局。
  • 支持治疗决策的证据正在出现,但最佳管理方式仍有许多问题待解。

研究设计与样本

  • 本文为Viewpoint观点性综述,总结血栓病理生理及相关实验室与临床发现。
  • 文章重点讨论住院重症COVID-19患者凝血病管理的关键考虑。

主要发现

  • SARS-CoV-2感染炎症反应可引起急性期反应和内皮功能障碍,促成COVID-19相关凝血病。
  • COVID-19相关凝血病的临床和实验室特征在某些方面不同于经典弥散性血管内凝血。

关键数值与推荐

  • 管理考虑包括凝血评估、血栓栓塞并发症识别、抗血栓预防和治疗性抗凝的使用。
  • 出院后延长血栓预防的安全性和获益尚待进行中试验结果确定。

临床怎么用

  • 住院重症COVID-19患者应关注凝血评估与血栓栓塞并发症识别。
  • 抗血栓预防与治疗性抗凝是住院重症COVID-19凝血病管理的关键考虑。
  • 出院后延长血栓预防需等待试验结果,暂不作为既定推荐。

局限性

  • 本文为观点性综述,未报告原始研究样本量、效应量或P值。
  • 支持治疗决策的证据仍在出现,最佳管理方式尚不明确。
  • 出院后延长血栓预防的安全性和获益尚待进行中试验确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A proportion of people infected with SARS-CoV-2 develop moderate or severe COVID-19, with an increased risk of thromboembolic complications. The inflammatory response to SARS-CoV-2 infection can cause an acute-phase response and endothelial dysfunction, which contribute to COVID-19-associated coagulopathy, the clinical and laboratory features of which differ in some respects from those of classic disseminated intravascular coagulation. Understanding of the pathophysiology of thrombosis in COVID-19 is needed to develop approaches to management and prevention, with implications for short-term and long-term health outcomes. Evidence is emerging to support treatment decisions in patients with COVID-19, but many questions remain about the optimum approach to management. In this Viewpoint, we provide a summary of the pathophysiology of thrombosis and associated laboratory and clinical findings, and highlight key considerations in the management of coagulopathy in hospitalised patients with severe COVID-19, including coagulation assessment, identification of thromboembolic complications, and use of antithrombotic prophylaxis and therapeutic anticoagulation. We await the results of trials that are underway to establish the safety and benefits of prolonged thromboprophylaxis after hospital discharge.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Vincent JL, Levi M, Hunt BJ, et al. Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia. Lancet Respir Med. 2021. PMID: 34838161. doi:10.1016/S2213-2600(21)00455-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。